Is AOD-9604 Legal in Massachusetts?

What AOD-9604 Is and Why Its Legal Status Matters

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176 through 191 of the human growth hormone (hGH) sequence. Researchers originally developed it at Monash University in Australia to reproduce the lipolytic (fat-breaking) properties of hGH without the insulin-resistance and IGF-1-mediated growth effects of the full molecule.

The compound attracted commercial interest after early clinical trials showed dose-dependent reductions in body fat. A Phase IIb/III program by Metabolic Pharmaceuticals ran through the early 2000s, with a 12-week randomized controlled trial (N=300) showing modest but statistically significant fat loss at oral doses of 1 mg per day compared to placebo. That program did not proceed to FDA approval, and no New Drug Application (NDA) was ever granted for any AOD-9604 product in the United States.

Why FDA Approval Status Shapes Everything

Because no finished drug product containing AOD-9604 has received FDA approval, there is no legal pathway to dispense it as a commercially manufactured pharmaceutical. The only potential route to legal patient access inside the United States is through compounding pharmacies, which operate under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDCA). Understanding those two sections is the foundation for understanding whether a Massachusetts patient can legally obtain AOD-9604.

The FDA's authority over compounded drugs derives directly from the FDCA, as amended by the Drug Quality and Security Act (DQSA) of 2013. Full DQSA text is available through the FDA.

The Federal Compounding Framework: 503A vs. 503B

The FDCA creates two distinct categories of compounding pharmacy, each with different rules about which bulk drug substances may be used.

Section 503A: Traditional Compounding Pharmacies

A 503A pharmacy compounds medications for individual patients with valid prescriptions from licensed practitioners. These pharmacies may use bulk drug substances that appear on an FDA-published list (the "503A bulks list") or that are components of FDA-approved drugs. The FDA's current 503A bulks list is maintained at fda.gov.

AOD-9604 was submitted for consideration on this list but was placed in a "Category 2" designation, meaning the FDA determined there was insufficient clinical evidence to support its inclusion without further review. A Category 2 designation is not an outright prohibition, but it does mean 503A pharmacies cannot freely add AOD-9604 to compounded formulations in the way they can with substances on the affirmative list. The FDA's draft guidance on bulk substance nominations makes this distinction explicit. See the FDA's bulk substance nomination guidance here.

Section 503B: Outsourcing Facilities

503B outsourcing facilities produce larger batches of compounded drugs for hospitals and clinics, without requiring patient-specific prescriptions. They operate under stricter current Good Manufacturing Practice (cGMP) standards. 503B facilities may only use bulk substances that appear on the 503B-specific bulks list. AOD-9604 does not appear on that list, so 503B outsourcing facilities have no legal pathway to produce it for office use or clinical distribution. The FDA's 503B bulks list is here.

What "Category 2" Means in Practice

The practical consequence is that most compounding pharmacies in Massachusetts and across the country have chosen to stop preparing AOD-9604, or have significantly restricted their dispensing, to avoid FDA enforcement action. Pharmacies that continue to compound it operate in a legally ambiguous space where the FDA could take action under adulteration or misbranding provisions of the FDCA. The degree of enforcement risk is real, not theoretical. In 2023 and 2024, the FDA issued multiple warning letters to compounding pharmacies over peptide products that lacked adequate regulatory footing. FDA warning letters to compounding pharmacies are searchable at fda.gov.

Massachusetts State Law and AOD-9604

Massachusetts has not enacted any statute that specifically names AOD-9604 or classifies it as a controlled substance under state law. The Massachusetts Controlled Substances Act (M.G.L. C. 94C) mirrors the federal Controlled Substances Act schedules, and AOD-9604 does not appear in any schedule at the federal or state level. The federal Controlled Substances Act scheduling information is maintained by the DEA at dea.gov and mirrored in DEA regulatory publications linked through FDA resources.

Possession of AOD-9604 for personal use is not a criminal offense under Massachusetts law. However, that does not make it freely available. What Massachusetts law does require is that any pharmacy dispensing a compounded product must be licensed by the Massachusetts Board of Registration in Pharmacy (the Board). The Board enforces compliance with both state pharmacy regulations and applicable federal law, including FDCA compounding restrictions.

Massachusetts Board of Pharmacy Oversight

The Board's authority means that a Massachusetts-licensed 503A pharmacy that compounds AOD-9604 for patient use is potentially compounding a substance the FDA has placed in a restricted category. If the FDA escalates enforcement on AOD-9604-containing compounds, a Massachusetts pharmacy could face both federal action and state Board discipline. This dual-layer risk is why many Massachusetts compounding pharmacies have moved away from AOD-9604 even though no Massachusetts law explicitly prohibits it.

The Massachusetts Department of Public Health and the Board publish guidance that generally tracks FDA standards for compounded preparations. Clinicians in Massachusetts who prescribe compounded AOD-9604 should be aware that prescribing an unapproved drug compounded outside the FDCA framework may expose them to Massachusetts Medical Practice Act concerns, though no prosecutions specifically for AOD-9604 prescribing have been publicly reported.

The Medical Practice Act Angle

Massachusetts General Laws c. 112, sections 2 through 9 govern the practice of medicine. Prescribing a preparation that falls outside recognized medical practice standards could theoretically invite Board of Registration in Medicine review, particularly if a patient experiences harm. This is a risk-management consideration, not a criminal prohibition. Clinicians who do prescribe AOD-9604 in Massachusetts typically do so within an informed-consent framework that documents the experimental or off-label nature of the compound and the absence of FDA approval.

Clinical Evidence Base: What the Trials Actually Show

The legal ambiguity around AOD-9604 is directly connected to its thin clinical evidence base. The FDA's Category 2 determination reflects a genuine evidentiary gap.

The Metabolic Pharmaceuticals Trials

The most frequently cited human data come from a series of trials conducted in Australia and registered with international trial registries. A 12-week Phase II randomized controlled trial (N=300) tested oral AOD-9604 at 1 mg/day versus placebo and reported a statistically significant reduction in body fat mass (P<0.05) with no significant changes in blood glucose, IGF-1, or insulin levels. The absence of IGF-1 stimulation was considered a safety advantage over full-length hGH.

No large-scale Phase III trial meeting FDA standards was completed. The absence of that data is precisely why the compound remains unapproved. For context on FDA Phase III requirements for obesity drugs, see the FDA guidance on developing drugs for weight management.

Preclinical Data

Animal studies, primarily in obese rodent models, showed AOD-9604 reduced adipose tissue accumulation and body weight without affecting linear growth or producing hyperglycemia. A study published through NCBI-indexed journals demonstrated that AOD-9604 modulated fat metabolism via beta-3 adrenergic receptor pathways rather than through the GH receptor, which may explain the dissociated metabolic profile. See related peptide metabolism research indexed at PubMed.

The clinical translation of rodent fat-loss data to humans has been inconsistent across metabolic pharmacology, and AOD-9604 is no exception. The Phase IIb/III oral dose trials produced smaller effects than the preclinical data predicted.

Cartilage and Joint Repair Research

A separate line of investigation has examined AOD-9604 in the context of cartilage repair, with researchers hypothesizing that the peptide fragment may support chondrocyte function. This research is even earlier-stage than the fat-loss data, consisting primarily of in vitro and animal work. No completed, peer-reviewed randomized controlled trial in humans on cartilage outcomes has been published in a major indexed journal as of mid-2024.

How to Legally Access AOD-9604 in Massachusetts: A Decision Framework

Given the regulatory complexity, patients in Massachusetts who are interested in AOD-9604 should think through the following steps before pursuing access.

Step 1: Consult a Licensed Massachusetts Clinician

No compounding pharmacy in Massachusetts may legally dispense a compounded preparation without a valid prescription from a licensed practitioner with a bona fide patient-prescriber relationship. The first requirement is a clinical evaluation, not a direct-to-consumer purchase. A clinician can assess whether any weight-management or metabolic therapy is appropriate and, if so, whether the evidentiary and regulatory risks of AOD-9604 are acceptable for that patient.

Step 2: Identify a 503A Pharmacy Willing to Compound

A small number of 503A compounding pharmacies continue to prepare AOD-9604 under the rationale that the Category 2 designation does not constitute an outright prohibition. Patients and clinicians who proceed should confirm in writing that the pharmacy is licensed by the Massachusetts Board of Registration in Pharmacy and is operating within its understanding of current FDA guidance. Asking the pharmacy for its legal rationale and for certificates of analysis (CoA) on the bulk substance is reasonable due diligence.

Step 3: Understand the Enforcement Risk

FDA enforcement against compounding pharmacies for peptide products has increased. A 2023 FDA warning letter campaign targeted pharmacies compounding a range of peptides, including those with Category 2 or unevaluated status. Patients who obtain AOD-9604 through a pharmacy that subsequently receives FDA enforcement action may lose access abruptly. This is a known, documented risk and not a theoretical one.

Step 4: Avoid Unregulated Online Sources

Research-chemical vendors sell AOD-9604 labeled "for research use only." Purchasing these products for human use violates both the vendor's stated terms and potentially FDA import and FDCA provisions. Independent laboratory testing of research-grade peptides from unregulated suppliers has found contamination rates that create genuine safety concerns. A 2022 analysis of gray-market peptide products found that a meaningful proportion contained either no detectable active peptide or significant impurities. For context on compounding quality standards, see FDA cGMP guidance.

AOD-9604 Compared to FDA-Approved Weight Loss Options

Patients considering AOD-9604 in Massachusetts should understand that several FDA-approved medications exist for chronic weight management, with substantially stronger evidence bases.

Semaglutide 2.4 mg (Wegovy), approved by the FDA in June 2021, produced 14.9% mean body weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% with placebo (P<0.001). The STEP-1 trial was published in the New England Journal of Medicine.

Tirzepatide 15 mg (Zepbound), FDA-approved in November 2023, produced up to 20.9% mean body weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) versus 3.1% with placebo (P<0.001). The SURMOUNT-1 trial is indexed at PubMed.

No head-to-head trial comparing AOD-9604 to semaglutide or tirzepatide has been conducted. The effect sizes from the AOD-9604 Phase II trials are substantially smaller than those achieved by GLP-1 receptor agonists in large, well-controlled studies.

The Endocrine Society's clinical practice guideline on obesity pharmacotherapy, updated in 2021, recommends using FDA-approved agents as first-line therapy and reserves discussion of unapproved compounds to investigational contexts. See the Endocrine Society obesity guideline at academic.oup.com.

What Massachusetts Patients and Clinicians Should Know Right Now

The regulatory posture on AOD-9604 is not static. The FDA's bulk substance review process is ongoing, and the compound's Category 2 status could change if sponsors submit additional clinical data meeting FDA standards. As of mid-2024, no sponsor has publicly filed a new IND or supplemental NDA for AOD-9604.

Massachusetts clinicians considering AOD-9604 prescribing should consult the Massachusetts Medical Society's current guidance on off-label prescribing and verify the dispensing pharmacy's compliance status directly with the Massachusetts Board of Registration in Pharmacy before writing a prescription.

The American Society of Addiction Medicine and the Obesity Medicine Association have not issued specific position statements on AOD-9604 as of this writing, which itself reflects the compound's marginal status in mainstream clinical practice.

A prescribing clinician in Massachusetts considering AOD-9604 would be, in the words of the FDA's own bulk substance guidance, operating outside a framework where "adequate information exists to support [the substance's] use in compounded preparations" under 503A standards, a characterization with direct clinical and liability implications.